11/5/2026

speaker
Conference Call Operator
Operator

Good afternoon and welcome to the MOBIA Medical Third Quarter 2026 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's prepared remarks, we will conduct a question and answer session. Please note that today's call is being recorded. I would now like to turn the call over to Louisa Smith of Gilmartin Group Investor Relations for MOBIA Medical. Louisa, please go ahead.

speaker
Louisa Smith
Investor Relations, Gilmartin Group

Good afternoon and thank you for being on today's call. Joining me from Mobia Medical are Richard Foust, President and Chief Executive Officer, and Bunker Curnes, Chief Financial Officer. Earlier today, Mobia Medical issued a press release announcing financial results for the quarter ended September 30th, 2026. Copy of the press release is available on the investor relations section of the company's website. Before we begin, I would like to remind you that management will make remarks during this call that constitute forward-looking statements within the meaning of the federal securities laws and that are being made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that relate to expectations or predictions of future events, results, or performance, including our full year 2026 revenue guidance, are forward-looking statements. These statements involve material risks and uncertainties that could cause actual results or events to differ materially from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a full list and description of the risks and uncertainties associated with our business, please refer to the section captioned Risk Factors and Management Discussion and Analysis of Financial Condition and Results of Operations and our filings with the Securities and Exchange Commission. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, November 5th, 2026. Mobia Medical disclaims any intention or obligation, except as required by law, to update or revise any forward-looking statements, whether because of new information, future events or otherwise. With that, I will now turn the call over to Richard.

speaker
Richard Foust
President and Chief Executive Officer

Thank you, Louisa. Good afternoon, everyone, and thank you for joining us today. We are pleased to welcome you to MOBIA Medical's Q3 2026 earnings call and are eager to share some details behind our strong third quarter performance. But first, we will begin with a real patient story that grounds us in why we do this work. Bill was 52 at the height of his career and in excellent physical condition. when he suffered an ischemic stroke after his daily run. He lost nearly all function in his right arm and hand that day. Over the next three months, he underwent intensive physical therapy, but his arm remained immobile. Because the hospital where Bill was treated was a Vivistem Center, his care team brought him back for evaluation once his recovery plateaued. and he began VidaStem Therapy six months after his stroke. After just six weeks of VidaStem Therapy, he had made more progress than in the previous six months. He was now dressing independently, tying his shoes with both hands and preparing meals. That was in 2022 and today there is nothing he cannot do independently. Bill's story shows what is possible with Viva Stem Therapy, and his story is not an outlier. Every day we hear from enthusiastic patients whose lives have been changed with Viva Stem Therapy. These patient stories are why we are so committed to this mission, and this quarter's results show that our work is paying off. Let me take you through our Q3 results and outlook for the rest of 2026. Revenue totaled $15.6 million for the quarter, representing a 73% growth over the prior year. With this performance and the strong fundamentals of the business, we are raising our full year revenue guidance. We now expect total 2026 revenue in the range of $57.0 million to $57.5 million, up from our prior guidance of $54 million to $56 million. Bunker will cover additional financial details and guidance assumptions later in our remarks. This quarter's performance reflects the strong fundamentals of our business. We address a large unmet need with a clinically validated solution that is generating patient demand, backed by strong market access and a favorable financial profile. Let me take a moment to discuss each of those elements. First, we are addressing a compelling unmet need for a highly motivated patient population that is symptomatic. There are approximately 9 million ischemic stroke survivors in the United States, many living with lasting impairments in their arms and hands. And until Vivistem therapy, there were no proven options once their recovery plateaued. This is why patients and healthcare providers are eager to adopt Vivistem therapy. The first and only clinically validated FDA-approved device for chronic ischemic stroke survivors with moderate to severe upper extremity impairments. Importantly, we have successfully treated patients several decades after their strokes. With Vivistem therapy, there is no expiration date on recovery. Second, Vivistem therapy is backed by strong and growing clinical evidence. and physician support. Our published clinical data demonstrates meaningful clinical improvement, durability through two years and reproducibility in real world settings. This evidence alongside growing adoption is driving increased awareness in the physician community. In August, we were pleased to announce that the American Heart Association and American Stroke Association revised their stroke Dr. Joseph Levy, Dr. Joseph Levy, Dr. Joseph Levy, As we continue to collect and publish real-world data, we believe that similar recognition from additional professional societies will present and that this will serve as a key building block in establishing broad utilization and payer coverage across the country. Third, we continue to be well-positioned on reimbursement with a well-established Category 1 CPT code associated with an average Medicare payment rate for approximately $45,000, and a highly effective in-house prior authorization and market access team, ViviStem therapy is accessible to patients and hospitals are getting paid for performing the procedure. With a large serviceable market, which we estimate to be over $30 billion in the U.S. alone, a highly valued product, and a gross margin above 80%, We have all the ingredients for a sustainable, high-growth business that can create operating leverage at scale. We have a unique opportunity in front of us. Our commercial engine is optimized to capture it effectively through a thoughtful process of building new territories, launching business and programs, and engaging patients in the stroke ecosystem. I'm going to dive a little bit deeper into the specifics of what this market build looks like. Our field team is organized into territories, each with a territory manager, or TM, and a therapy development specialist, or TDS. TMs are responsible for partnering with hospitals and healthcare providers, while TDSs partner with therapy sites and support patient education in the community. TMs focus on engaging with stroke hospitals. Stroke hospitals have the expertise and infrastructure to lead the way in defining new standards of care for chronic stroke recovery. They are the center of the stroke care ecosystem with connections to occupational and physical therapy sites in the community that enable the continuity of care beyond acute survival and into chronic recovery. We estimate there is a relatively concentrated base of approximately 1,500 primary and comprehensive stroke centers across the United States. At each stroke hospital, our TMs build relationships with the entire stroke care team, including neurosurgeons, neurologists, physiatrists, and stroke coordinators. Our TMs learn how acute stroke care currently works at each site and then determine how VivisDem programs can fit in so that the hospital has a comprehensive chronic stroke recovery pathway. In concert, Our TDSs work with the stroke care ecosystem outside of the hospital, such as therapy sites and patient support groups to drive awareness and referrals. Our TDSs also onboard the therapy sites around the stroke hospital that will deliver in-clinic therapy to ViviSTEM patients and partner with these sites to ensure care continuity and successful patient outcomes. Putting that together, Each new ViviSTEM program we open is a stroke hospital that will screen and implant patients with connections to the therapy sites that will identify eligible patients and provide in-clinic ViviSTEM therapy after implant. This is what constitutes a high-quality, sustainable ViviSTEM program. Importantly, we are not disrupting existing care pathways. Rather, we are extending the treatment continuum beyond the acute and subacute phases. Through this process, we are creating advocates for ViviSTEM therapy, not just creating users of our technology. Our third quarter reflects continued success in building the market for ViviSTEM therapy, increased awareness and recognition among the physician community, ViviSTEM programs built with care and attention, and more patients experiencing new possibilities in their recovery journey. Whether they are returning to their favorite hobby, picking up their grandchild again, or cooking a meal on their own, our patients continue regaining independence that was once out of their reach. That is Mobia's why, and we are just getting started. With that, I will turn the call over to Bunker to review our third quarter financial results. Bunker?

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API